ABBV-382 + ABBV-382 + Placebo for ABBV-382
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Human Immunodeficiency Virus (HIV)
Conditions
Human Immunodeficiency Virus (HIV)
Trial Timeline
Apr 16, 2021 → Aug 14, 2023
NCT ID
NCT04554966About ABBV-382 + ABBV-382 + Placebo for ABBV-382
ABBV-382 + ABBV-382 + Placebo for ABBV-382 is a phase 1 stage product being developed by AbbVie for Human Immunodeficiency Virus (HIV). The current trial status is completed. This product is registered under clinical trial identifier NCT04554966. Target conditions include Human Immunodeficiency Virus (HIV).
What happened to similar drugs?
14 of 20 similar drugs in Human Immunodeficiency Virus (HIV) were approved
Approved (14) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04554966 | Phase 1 | Completed |
Competing Products
20 competing products in Human Immunodeficiency Virus (HIV)